R2 in the Treatment of Follicular Lymphoma

Shanghai Jiao Tong University logo

Shanghai Jiao Tong University

Status and phase

Unknown
Phase 2

Conditions

Follicular Lymphoma

Treatments

Drug: Revlimid

Study type

Interventional

Funder types

Other

Identifiers

NCT03715309
RJ-R2

Details and patient eligibility

About

Lenalidomide Based Immunotherapy in the Treatment of FL

Full description

Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma

Enrollment

115 estimated patients

Sex

All

Ages

16 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients diagnose as de novo or relapse refractory FL grade 1-3A .

No history of stem cell transplantation.

Written informed consent.

Exclusion criteria

Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study.

Clinically significant active infection.

Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule.

Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.

Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment.

Patients who are pregnant or breast-feeding.

HIV infection.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

115 participants in 1 patient group

Revlimd
Experimental group
Treatment:
Drug: Revlimid

Trial contacts and locations

1

Loading...

Central trial contact

Weili Zhao

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems